Medicare drug coverage

Aimovig: 2027 Medicare Part D coverage

4,379 of 5,495 Part D plans (80%) list Aimovig on their 2027 formulary, the same share as 2026. 100% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Aimovig is number 138 by total Medicare Part D spending in 2024 ($306 million). Plans that list it most often put it on tier 3. Counts use 6 RxNorm products for this name.

Aimovig Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it4,401 (80%)4,379 (80%)no change
Prior authorization (of plans that list it)4,359 (99%)4,344 (99%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)4,313 (98%)4,373 (100%)+2 points
Any of the three (of plans that list it)4,391 (100%)4,373 (100%)no change
Not listed or restricted (of all plans)5,508 (100%)5,489 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Aimovig formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1150 (3%)113 (3%)
Tier 252 (1%)279 (6%)
Tier 34,188 (95%)3,978 (91%)
Tier 411 (0%)9 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 70 of them (2%) added prior authorization, step therapy, or a quantity limit for Aimovig, and 46 stopped listing it.

Aimovig: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 202746 (1%)
Listed it in 2027, not in 202626 (1%)
Moved it to a higher tier44 (1%)
Added prior authorization12 (0%)
Added step therapy0 (0%)
Added a quantity limit58 (1%)
Added at least one of the three70 (2%)
Removed at least one of the three2 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Aimovig off the formulary or list it with prior authorization, step therapy, or a quantity limit. Massachusetts ranks first at 100%, with 91% of its plans using prior authorization or step therapy; Florida ranks last at 99%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Aimovig, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Massachusetts92100%91%no change
2New York215100%91%no change
3Pennsylvania324100%91%no change
4Ohio173100%86%no change
5Minnesota63100%86%no change
6Connecticut54100%85%no change
7Tennessee157100%84%no change
8Arizona148100%84%no change
9South Dakota30100%83%no change
10Michigan183100%83%no change
11Iowa64100%83%no change
12Texas412100%83%no change
13North Carolina177100%82%no change
14Delaware43100%81%no change
15New Jersey74100%81%no change
16North Dakota26100%81%no change
17Oregon92100%80%no change
18Alabama115100%80%no change
19California397100%79%no change
20Missouri171100%79%no change
21New Mexico68100%78%no change
22Illinois133100%77%no change
23Wisconsin97100%77%no change
24Indiana140100%77%no change
25Mississippi105100%75%no change
26Nebraska51100%75%no change
27Nevada100100%74%no change
28Kansas84100%74%no change
29Idaho45100%73%no change
30Arkansas86100%73%no change
31West Virginia70100%73%no change
32South Carolina91100%73%no change
33Oklahoma81100%70%no change
34Georgia151100%70%no change
35Hawaii50100%70%no change
36Louisiana126100%70%no change
37Maine52100%69%no change
38Rhode Island29100%69%no change
39Washington114100%68%no change
40Colorado106100%67%no change
41Kentucky123100%64%no change
42Utah53100%64%no change
43Virginia145100%64%no change
44Maryland49100%63%no change
45District of Columbia21100%62%no change
46New Hampshire25100%60%no change
47Alaska9100%56%no change
48Wyoming13100%46%no change
49Vermont14100%43%no change
50Montana27100%30%no change
51Florida54999%69%+1 point

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Aimovig off or restrict it.

Aimovig coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.8840%none list it100%no change0
UnitedHealth Group, Inc.850100%100%100%no change0
Devoted Health, Inc.728100%100%100%no change0
CVS Health Corporation633100%100%100%no change0
Elevance Health, Inc.294100%100%100%no change0
Centene Corporation26887%100%100%no change0
Health Care Service Corporation231100%100%100%no change0
Kaiser Foundation Health Plan, Inc.1120%none list it100%no change0
Highmark Health98100%100%100%no change0
SCAN Group85100%100%100%no change54
Alignment Healthcare USA, LLC77100%100%100%no change0
Guidewell Mutual Holding Corporation557%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.43100%100%100%no change0
Molina Healthcare, Inc.43100%100%100%no change0
Corewell Health40100%100%100%no change0
Zing Health Consolidator, Inc36100%100%100%no change0
CAPITAL BLUE CROSS35100%100%100%no change0
Medica Holding Company31100%100%100%no change0
UPMC Health System30100%100%100%no change0
Universal Health Services, Inc.29100%100%100%no change0
MHH Healthcare, L.P.26100%100%100%no change0
Independence Health Group, Inc.25100%100%100%no change0
Point32Health, Inc.23100%100%100%no change0
BlueCross BlueShield of Tennessee22100%100%100%no change0
California Physicians' Service22100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Aimovig?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing